NEFL and myeloid sarcoma: In this five-year prospective mono-center study, we therefore further extended the efficacy and safety data of ALZ, included all commonly used MS-related outcomes, and added data of glial fibrillary acidic protein (GFAP), reflecting astrogliosis, and neurofilament light (NfL), reflecting axonal damage, in cerebrospinal fluid (CSF) and serum.